查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲細胞化驗分析市場：分析與預測（2023-2032）
市場調查報告書
商品編碼
1410671

歐洲細胞化驗分析市場：分析與預測（2023-2032）

Europe Cell-Based Assay Market: Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 75 Pages | 商品交期: 1-5個工作天內

價格

歐洲細胞化驗分析市場規模預計將從 2023 年的 51.7 億美元增至 2032 年的 111.2 億美元，在 2023-2032 年預測期內複合年成長率為 8.88%。

在製藥業的藥物研發努力以及這些檢測相對於傳統方法的獨特優勢的推動下，細胞化驗分析市場正在快速成長。模仿人類生理學、早期預測藥物療效和毒性以及個體化醫療保健的能力正在推動需求。慢性病的增加和政府的支持措施進一步放大了這一趨勢，市場有望大幅擴張。

主要市場統計數據
預測期 2023-2032
2023年評估價值 51.7億美元
2032年預測 112億美元
複合年成長率 8.88%

由於多種因素的綜合作用，歐洲細胞化驗分析市場正在經歷快速成長。製藥和生物技術領域的快速成長，重點是高效的藥物研發和個人化醫療，正在推動對這些強大工具的需求。細胞化驗分析提供了一種比傳統動物模型更貼近人類且更具成本效益的替代方案，可快速篩檢候選藥物並更深入地了解作用機制。對學術研究的投資增加以及政府促進生命科學創新的努力進一步支持了這一轉變。然而，高昂的設備成本和嚴格的法律規範挑戰需要策略合作夥伴關係和技術進步，才能充分發揮這個快速發展的市場的潛力。

該報告考察了歐洲細胞化驗分析市場，並提供了市場概述、按國家和公司分類的趨勢以及進入市場的公司概況。

目錄

執行摘要

第1章 定義

第2章 研究範圍

第3章調查方法

第4章市場概況

  • 市場介紹
    • 細胞化驗分析類型
  • 工業細胞化驗分析的現況與未來狀況
  • 細胞化驗分析市場的新興技術與應用
  • 當前市場規模和成長潛力，十億美元，2022-2032
  • COVID-19 對細胞化驗分析市場的影響
    • 對細胞化驗分析公司的影響

第5章業界考察

  • 概述
  • 歐洲法律要求和框架

第6章市場動態

  • 概述
  • 影響分析
    • 市場促進因素
    • 市場抑制因素
    • 市場機會

第7章競爭形勢

  • 競爭形勢概覽
    • 主要進展
    • 產品發布和擴展活動
    • 併購活動
    • 協同效應
    • 許可證和合約活動
  • 市場佔有率分析（2022）
  • 成長佔有率分析（2021-2022）
    • 成長佔有率分析（按公司）

第8章 歐洲

  • 概述
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他地區

第9章 公司簡介

Product Code: BHL1787SS

“The Europe Cell-Based Assay Market Expected to Reach $11.12 Billion by 2032.”

Introduction to Europe Cell-Based Assay Market

The Europe cell-based assay market is expected to reach $11.12 billion by 2032 from $5.17 billion in 2023, at a CAGR of 8.88% during the forecast period 2023-2032. The Cell-Based Assay Market is surging, driven by the pharmaceutical industry's escalating drug discovery efforts and the inherent advantages of these assays over traditional methods. Their ability to mimic human physiology, predict drug efficacy and toxicity early, and personalize medicine fuels demand. This trend is further amplified by rising chronic disease prevalence and supportive government initiatives, fostering a market poised for significant expansion.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$5.17 Billion
2032 Forecast$11.12 Billion
CAGR8.88%

Market Introduction

The European cell-based assay market is experiencing a surge, fueled by a confluence of factors. The burgeoning pharmaceutical and biotechnology sectors, with their focus on efficient drug discovery and personalized medicine, are driving demand for these powerful tools. Cell-based assays offer a more human-relevant and cost-effective alternative to traditional animal models, allowing for rapid screening of drug candidates and a deeper understanding of their mechanisms of action. This shift is further bolstered by rising investments in academic research and government initiatives promoting life sciences innovation. However, challenges such as high instrumentation costs and stringent regulatory frameworks necessitate strategic partnerships and technological advancements to unlock the full potential of this rapidly evolving market.

Market Segmentation:

Segmentation 1: by Country

  • U.K.
  • France
  • Italy
  • Germany
  • Spain
  • Rest-of-Europe

Segmentation 2: by Company

  • Merck KGaA
  • Lonza Group AG

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.

Competitive Strategy: Key players in the Europe cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

  • 1.1. Inclusion and Exclusion Criteria

2. Research Scope

  • 2.1. Key Questions Answered in the Report:

3. Research Methodology

  • 3.1. Cell-Based Assay Market: Research Methodology
  • 3.2. Primary Data Sources
  • 3.3. Secondary Data Sources
  • 3.4. Market Estimation Model
  • 3.5. Criteria for Company Profiling

4. Markets Overview

  • 4.1. Market Introduction
    • 4.1.1. Types of Cell-Based Assays
  • 4.2. Current and Future State of Cell-Based Assays in Industries
  • 4.3. Emerging Technologies and Applications in the Cell-Based Assay Market
  • 4.4. Current Market Size and Growth Potential, $Billion, 2022-2032
  • 4.5. COVID-19 Impact on Cell-Based Assay Market
    • 4.5.1. Impact on Cell-Based Assay Companies

5. Industry Insights

  • 5.1. Overview
  • 5.2. Legal Requirements and Frameworks in Europe

6. Market Dynamics

  • 6.1. Overview
  • 6.2. Impact Analysis
    • 6.2.1. Market Drivers
      • 6.2.1.1. Increase in Demand for Cell-Based Assay in Drug Discovery and Development
      • 6.2.1.2. Rise in Life Sciences Research Investments
      • 6.2.1.3. Technological Advancements
    • 6.2.2. Market Restraints
      • 6.2.2.1. High Cost
      • 6.2.2.2. Lack of Standardization
    • 6.2.3. Market Opportunities
      • 6.2.3.1. Increased Focus on Regenerative Medicine
      • 6.2.3.2. Emergence of Novel Gene Editing Technologies

7. Competitive Landscape

  • 7.1. Competitive Landscape Overview
    • 7.1.1. Key Developments
    • 7.1.2. Product Launch and Expansion Activities
    • 7.1.3. Merger and Acquisition Activities
    • 7.1.4. Synergistic Activities
    • 7.1.5. License and Agreement Activities
  • 7.2. Market Share Analysis (2022)
  • 7.3. Growth-Share Analysis (2021-2022)
    • 7.3.1. Growth-Share Analysis (by Company)

8. Europe

  • 8.1. Overview
  • 8.2. Europe
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Rest-of-Europe

9. Company Profiles

  • 9.1. Overview
    • 9.1.1. Merck KGaA
      • 9.1.1.1. Company Overview
      • 9.1.1.2. Role of Merck KGaA in the Cell-Based Assay Market
      • 9.1.1.3. Major Product: Key Specifications
      • 9.1.1.4. Key Competitors
      • 9.1.1.5. Analyst Perspective
    • 9.1.2. Lonza Group AG
      • 9.1.2.1. Company Overview
      • 9.1.2.2. Role of Lonza Group AG in the Cell-Based Assay Market
      • 9.1.2.3. Major Product: Key Specifications
      • 9.1.2.4. Key Competitors
      • 9.1.2.5. Analyst Perspective

List of Tables

  • Table 1: Current and Future State of Cell-Based Assay in Industries
  • Table 2: Utilizing the Potential of Cell-Based Assays: Novel Instruments and Methodologies in 2020-2021

List of Figures

  • Figure 1: Impact Analysis of Drivers, Challenges, and Opportunities on the Cell-Based Assay Market
  • Figure 2: Cell-Based Assay Market (by Region), 2022
  • Figure 3: Cell-based Assay Market Methodology
  • Figure 4: Primary Research Methodology
  • Figure 5: Top-Down Approach (Segment-Wise Analysis)
  • Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 7: Cellular Processes Utilized to Investigate the Impacts in Cell-Based Assays
  • Figure 8: Emerging Technologies in the Cell-Based Assay Market
  • Figure 9: Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 10: Impact of COVID-19 on Cell-Based Assay Companies
  • Figure 11: Cell-Based Assay Market - Market Dynamics
  • Figure 12: Total U.S. Life Sciences Venture Capital Funding, $Billion, 2016-2021
  • Figure 13: Uses of Cell-based Assays in Regenerative Medicine
  • Figure 14: Share of Key Developments and Strategies, January 2020 to March 2023
  • Figure 15: Share of Product Launch and Expansion Activities (by Company), January 2020 to March 2023
  • Figure 16: Share of Merger and Acquisition Activities (by Company), January 2020 to March 2023
  • Figure 17: Share of Synergistic Activities (by Company), January 2020 to March 2023
  • Figure 18: Market Share Analysis for Cell-Based Assay Market, 2022
  • Figure 19: Growth-Share Analysis for Cell-Based Assay Market (by Company), 2021-2022
  • Figure 20: Cell-Based Assay Market Snapshot (by Region)
  • Figure 21: Cell-Based Assay Market (by Region), $Billion, 2022-2032
  • Figure 22: Europe Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 23: Europe: Market Dynamics
  • Figure 24: Europe Cell-Based Assay Market (by Country), $Billion, 2022-2032
  • Figure 25: Germany Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 26: U.K. Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 27: France Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 28: Italy Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 29: Spain Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 30: Rest-of-Europe Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 31: Total Number of Companies Profiled
  • Figure 32: Merck KGaA: Product Portfolio
  • Figure 33: Lonza Group AG: Product Portfolio